In a xenograft mouse model of multiple myeloma and BCL‐2, ABT‐263 exhibited increased toxicity when mice were treated with the BCL‐2, BCL‐XL, and BCL‐W inhibitor ABT‐263 (Tse et al., 2008). This evidence concerns the gene BCL2 and plasma cell myeloma.